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Short-term reductions in the probability of disease recurrence associated with adding
bevacizumab to an adjuvant chemotherapy regimen for patients with early TNBC were 
projected to improve quality-adjusted survival and potentially be cost-effective given 
recent discussions concerning willingness-to-pay thresholds in the UK.
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OBJECTIVES: To evaluate the cost-effectiveness of fulvestrant as an additional hor-
monal agent in the treatment sequence of postmenopausal women with ER advanced 
or metastatic breast cancer from the perspective of the Israeli health care system. 
METHODS: A Markov model was developed to compare two identical cohorts of 
patients: one with fulvestrant as either a 2nd or 3rd line therapy and the other without.
Treatment efﬁ cacy and other clinical parameters were estimated using a systematic 
review of RCTs and survey of oncologists in the UK and Israel. Unit costs for drugs
and other health services were estimated from nationally published sources, and 
reported in 2008 NIS. Utility values for each health state were derived from a survey 
of seven oncologists in the UK. All future costs and beneﬁ ts (QALYs) were discounted
at 3%. One-way and probabilistic sensitivity analyses were conducted to examine the
robustness of our base-case results. RESULTS: The addition of fulvestrant to the
treatment sequence as a 2nd line therapy resulted in a mean gain of 0.04 QALYs and 
cost-savings of over 8,000 NIS per patient. Addition of fulvestrant as a 3rd line therapy
resulted in a gain of 0.03 QALYs and savings of approximately 13,000 NIS. Sensitivity 
analyses demonstrated these results to be robust under a wide range of assumptions. 
CONCLUSIONS: Our analysis demonstrated that addition of fulvestrant to the treat-
ment sequence of ER advanced breast cancer patients is highly likely to be a cost-
saving intervention strategy in Israel for both 2nd and 3rd line treatments.
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OBJECTIVES: Human papillomavirus (HPV) infection had been demonstrated as a 
major risk factor for cervical cancer. Vaccines against HPV-16 and HPV-18 appeared
highly efﬁ cacious in preventing HPV-16 and HPV-18 infections and cervical lesions 
including cervical cancer. However, only limited available data described the health
and economic implications of HPV vaccination in Taiwan. The objective of this study 
was to assess the cost-effectiveness of prophylactic HPV vaccination for prevention of 
cervical cancer in Taiwan. METHODS: We developed a Markov model to compare 
the health and economic outcomes of vaccinating preadolescent girls (at age of 12 
years old) for prevention of cervical cancer with current practice. Data were synthe-
sized from published papers, and whenever possible, those speciﬁ c to Taiwan were 
used. The economic analysis adopted the health care payer’s perspective, and only
direct medical costs were taken into account. Sensitivity analyses were performed to
account for important uncertainties and different vaccination scenario. RESULTS:
Under the assumption that the HPV vaccine would provide lifelong protection, vacci-
nation among preadolescent girls in Taiwan would result in a life expectancy gain of 
16.8 days or 21.2 quality-adjusted life days at a cost of US$287 as compared with 
the current screening practice. The incremental cost-effectiveness ratio (ICER) was 
US$6,236 per life year gained or US$4,946 per QALY gained given the discount rate 
of 3%. Sensitivity analyses showed that this ICER would remain far below US$30,000
per QALY even when vaccine compliance was unsatisfactory or vaccine-induced
immunity wanned that needed booster shot. CONCLUSIONS: Although gains in life 
expectancy may be modest at individual level, the results indicate that prophylactic
HPV vaccination on preadolescent girls in Taiwan would result in substantial popula-
tion beneﬁ ts, i.e., it is a very cost-effective strategy in public health.
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OBJECTIVES: The objective of the study was to compare the efﬁ cacy and treatment 
costs of FLUCAM versus FCR in the second line treatment of CLL in a one year time 
horizon under the Brazilian private health care system (BPS) perspective. METHODS:
A literature review was performed and two phase II trials were found, evaluating the 
efﬁ cacy of FLUCAM (JCO 2005;23:7024) or FCR (JCO 2005;23:4070). FLUCAM 
presented higher response rates and lower overall survival and time to disease progres-
sion than FCR. Grouping patients from both studies into risk groups, and assuming
median overall survivals of 11, 6 and 2 years for low, intermediate and high risk
patients, respectively, resulted in an expected median overall survival of 2.89 years for 
FLUCAM and 4.15 years for FCR. This reﬂ ects the higher disease severity in the 
FLUCAM study population at baseline. Therefore, it cannot be concluded through an 
indirect comparison that one treatment is superior to the other. Assuming equivalent 
efﬁ cacies for both treatments, a cost-minimization analysis was developed. Study
protocols were valued considering an average body surface of 1.7m2 and maximum 
prices to consumer for drugs. Antimicrobial prophylaxis and pre-treatment drugs were 
included. The average number of cycles administered was 4.2 cycles for both proto-
cols. Dose reductions were considered for FCR. Eighty-six of patients have received 
normal dosage, 13% had a level 1 dose reduction starting on the third cycle, and 1%
had a Level 1 reduction at Cycle 3 and a Level 2 reduction from Cycle 4. RESULTS:
Treatment costs found in one year were R$36,370 for FLUCAM and R$63,778 for
FCR, representing a cost reduction of R$27,408 (US$11,874) in favor of FLUCAM.
CONCLUSIONS: Assuming equivalent efﬁ cacies for both treatments, FLUCAM pre-
sented a lower total treatment cost than FCR, being a valuable alternative in face of 
budget constraints, for the BPS.
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OBJECTIVES: This burden of illness study was conducted to assess the 12-month
resource utilization and health care costs, along with the major drivers of those costs,
associated with an incident diagnosis of breast cancer (BC). METHODS: An analysis 
of incident BC patients identiﬁ ed using a claims database, was performed, for 2005,
2006, and 2007. BC patients and the age and gender matched comparator group (1:4) 
for each year, were required to have continuous enrollment in a plan and no breast
cancer diagnoses during the 18 months prior to the ﬁ rst diagnosis of breast cancer in 
the year. The BC and comparison groups were each described in terms of their health
care service use and health care costs, which were compared, using nonparametric 
Wilcoxon rank-sum tests, with mean values reported here for 2007. RESULTS: There 
were 25,298 women diagnosed with BC in 2007, in this database, and we selected
101,192 controls. The mean health care cost for the women diagnosed with BC was 
$26,227 vs. $5,996 for controls; p  0.001. The primary drivers for this more than
quadruple cost difference between the two groups were: prescription drugs ($5265 
vs. $1361; p  0.001); hospitalizations ($5,111 vs. $1,706; p  0.001); radiology
tests ($3592 vs. $352; p  0.001); and laboratory tests ($1284 vs. $195; p  0.001). 
Resource utilization over the 12-month period showed that the women with BC, when
compared to the control group, had a signiﬁ cantly greater (p  0.001) mean number
of prescriptions drugs (30 vs. 17); hospitalizations (0.3 vs. 0.1); radiology tests (14
vs. 3); and laboratory tests (23 vs. 8). The results were similar for analyses conducted 
on 2006 and 2005 data. CONCLUSIONS: The signiﬁ cantly higher 12-month resource
utilization and health care costs noted in women diagnosed with BC, compared to age 
and gender matched controls, are primarily driven by an increased need for prescrip-
tion drugs, hospitalizations, radiology tests, and laboratory tests.
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OBJECTIVES: Clinical trial results suggest that patients with PCBM may experience 
SREs an average of 16 months after the BM diagnosis. Prior studies examined the cost
of SREs in patients with PCBM but have not evaluated the period from BM diagnosis 
to development of SREs. We examined costs in men with PCBM before and after the
occurrence of SREs. METHODS: This study used claims data from a large, U.S. health
insurance plan spanning January 2003–December 2007. Patients were included in the 
analysis if they were male and had: diagnoses of PC and BM, at least one claim for 
hormonal therapy (HT) in the year prior to BM, a complete claims history and no
claims for malignancy in the year prior to BM diagnosis. SREs were identiﬁ ed based 
on CPT/ICD-9 codes and included radiotherapy, pathological fracture, surgery to the 
bone, spinal cord compression, or hypercalcemia. The impact of BM and SREs 
on total health care costs (i.e. inpatient, outpatient, pharmacy) for the period six 
months prior to BM ending with disenrollment or end of the study period was evalu-
ated using repeated-measures generalized linear model regression. RESULTS: Of 
216,554 PC patients, 10,520 had a diagnosis of BM, with 4,988 receiving HT in the
year prior to BM. Of these, 1385 met all inclusion criteria, including 652 (47%) with 
q1 SRE and 733 with no SRE (53%). Mean total health care costs were $23,481/
person-year (PY) in the 6 months prior to BM. On an adjusted basis, costs increase
by $5,722/PY with BM and no SREs (p  0.001) and by $17,202/PY with BM and 
SREs (p  0.001). BM without SREs was associated with 91% increase in hospitaliza-
tion risk; BM with SREs, a 181% increase in hospitalization risk. CONCLUSIONS:
BM are associated with increased total health care costs, even in the absence of SREs
in patients with PC.
